Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

NCT04742959 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

203

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Cholangiocarcinoma
HER2-negative Breast Cancer
Triple Negative Breast Cancer
Bladder Cancer
Small-cell Lung Cancer
Prostate Cancer
Thyroid Cancer
Sarcoma
Gastric Cancer
Gallbladder Cancer

Interventions

DRUG: TT-00420
COMBINATION_PRODUCT: Nab-Paclitaxel

Sponsor

TransThera Sciences (Nanjing), Inc.